What this means
The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model. The results showed that fat mass could be decreased by \~32%, while histology Oil Red O staining indicated a decrease of fat by almost 60%; in contrast, lean muscle mass increased by \~14%.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Completed
- Who can join
- Ages 60 and over
- Where
- 3 sites
The science
- Registered title
- RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration
- Trial ID
- NCT05525039 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Sarcopenia, Connective Tissue Diseases in Old Age, Musculoskeletal Abnormalities
- What is tested
- Low-magnitude High-frequency Vibration, β-hydroxy β-methylbutyrate (HMB) supplement, Protein supplement
- Sponsor
- Chinese University of Hong Kong
- Ages
- 60 Years to no maximum
- Dates
- First posted Sep 1, 2022 · updated Oct 21, 2026
Registry summary
The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model. The results showed that fat mass could be decreased by \~32%, while histology Oil Red O staining indicated a decrease of fat by almost 60%; in contrast, lean muscle mass increased by \~14%. On muscle strength, combined treatment increased twitch force, tetanic force and grip strength by \~30-66%. These in vivo results are very encouraging and the investigators should explore its potential in clinical translation. As VT and HMB supplement have been commercially available and their compliance rates are satisfactory, they can be translated to clinical application easily. The investigators' next step is to confirm its clinical efficacy, so that sarcopenia becomes a new indication of VT and HMB. The hypothesis is that combined treatment of VT and HMB can retard the progression of sarcopenia in human, in terms of muscle mass, muscle strength and performance.
Sites (3)
- Evangelical Luthera Church Social Service - Hong Kong, Hong Kong, Hong Kong
- The Chinese University of Hong Kong Jockey Club Centre for Osteoporosis Care and Control, Hong Kong, Hong Kong
- The Chinese University of Hong Kong, Department of Orthopaedics and Traumatology, 1/F Li Ka Shing Outpatient Clinic (North), PWH, Hong Kong, Hong Kong
